Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 6/2005

01.12.2005 | Original Article

Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients

verfasst von: Seiichirou Hoshino, Yuuichi Yamashita, Takafumi Maekawa, Takayuki Shirakusa

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 6/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

5-Fluorouracil (5-FU) has two major mechanisms by which it exerts its anticancer activity. One mechanism operates through the inhibition of thymidylate synthetase (TS) by the active metabolite 5-fluorodeoxyuridine 5’-monophosphate. The other mechanism is the incorporation of 5-FU into RNA. Using tumor tissue specimens from colon carcinoma patients given 5-FU by two different modes of administration, we investigated the effects of 5-FU on DNA and RNA.

Experimental design

Group A patients received 200 mg/day of 5-FU as a rapid infusion for 5 days preoperatively, and group B patients received 200 mg/day of 5-FU as a continuous infusion for 5 days preoperatively. Postoperatively, we analyzed the 5-FU concentration, 5-FU incorporation into RNA (F-RNA), and TS inhibition rate (TSIR) in normal tissue, cancerous tissue, and lymph nodes.

Results

The F-RNA concentration in tumor tissue from group A patients was higher than in tissue from group B patients. The TS concentrations in tumor tissue were significantly higher than in non-tumor tissue in both groups. In lymph nodes, the TSIR of group A was 78.5% and that of group B was 55.2%, a significant difference.

Conclusion

Bolus injection can be considered to be more effective with respect to RNA damage in tumor tissue. Especially in cases involving lymph node metastasis, bolus injection was effective with respect to DNA damage as well as RNA damage.
Literatur
1.
Zurück zum Zitat Carte SK, Friedman M (1974) Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1:111–129 Carte SK, Friedman M (1974) Integration of chemotherapy into combined modality treatment of solid tumors. Cancer Treat Rev 1:111–129
2.
Zurück zum Zitat Langenback RJ, Danenberg PV, Heidelberger C (1972) Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48:1565–1571CrossRefPubMed Langenback RJ, Danenberg PV, Heidelberger C (1972) Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun 48:1565–1571CrossRefPubMed
3.
Zurück zum Zitat Matsuoka H, Ueo H, Sugimachi K, Akiyoshi T (1992) Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 10:265–269PubMed Matsuoka H, Ueo H, Sugimachi K, Akiyoshi T (1992) Preliminary evidence that incorporation of 5-fluorouracil into RNA correlates with antitumor response. Cancer Invest 10:265–269PubMed
4.
Zurück zum Zitat Aschele C, Sobrero A, Federan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855–1864PubMed Aschele C, Sobrero A, Federan MA, Bertino JR (1992) Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 52:1855–1864PubMed
5.
Zurück zum Zitat Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308PubMed Meta-analysis Group In Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301–308PubMed
6.
Zurück zum Zitat Carlson R (1996) Continuous intravenous infusion chemotherapy. In: Perry MC (ed) The chemotherapy source book. MD Williams & Wilkins, Baltimore, pp 225–251 Carlson R (1996) Continuous intravenous infusion chemotherapy. In: Perry MC (ed) The chemotherapy source book. MD Williams & Wilkins, Baltimore, pp 225–251
7.
Zurück zum Zitat Sommer H, Santi DV (1974) Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 57:689–695CrossRefPubMed Sommer H, Santi DV (1974) Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenetetrahydrofolate. Biochem Biophys Res Commun 57:689–695CrossRefPubMed
8.
Zurück zum Zitat Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridine. Biochemistry 13:471–481CrossRefPubMed Santi DV, McHenry CS, Sommer H (1974) Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridine. Biochemistry 13:471–481CrossRefPubMed
9.
Zurück zum Zitat Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer. Clin Cancer Res 4:1243–1250PubMed Lenz HJ, Hayashi K, Salonga D, Danenberg KD, Danenberg PV, Metzger R, Banerjee D, Bertino JR, Groshen S, Leichman LP, Leichman CG (1998) p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer. Clin Cancer Res 4:1243–1250PubMed
10.
Zurück zum Zitat Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412 Johnston PG, Lenz HJ, Leichman CG, Danenberg KD, Allegra CJ, Danenberg PV, Leichman L (1995) Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55:1407–1412
11.
Zurück zum Zitat Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I, Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal cancer: methodological studies. Eur J Cancer 33:2278–2281CrossRefPubMed Edler D, Blomgren H, Allegra CJ, Johnston PG, Lagerstedt U, Magnusson I, Ragnhammar P (1997) Immunohistochemical determination of thymidylate synthase in colorectal cancer: methodological studies. Eur J Cancer 33:2278–2281CrossRefPubMed
12.
Zurück zum Zitat Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ (1993) Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 43:527–533 Chu E, Koeller DM, Johnston PG, Zinn S, Allegra CJ (1993) Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma. Mol Pharmacol 43:527–533
13.
Zurück zum Zitat Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890–899PubMed Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ (1989) Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:890–899PubMed
14.
Zurück zum Zitat Kanamura R, Kakuta H, Sato T, Ishioka C, Wakui A (1986) The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol 17:43–46CrossRefPubMed Kanamura R, Kakuta H, Sato T, Ishioka C, Wakui A (1986) The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro. Cancer Chemother Pharmacol 17:43–46CrossRefPubMed
15.
Zurück zum Zitat Santi DV, Hardy LW (1987) Catalytic mechanism and inhibition of tRNA (uracil-5-) methyltransferase: evidence for covalent catalysis. Biochemistry 26:8599–8606 Santi DV, Hardy LW (1987) Catalytic mechanism and inhibition of tRNA (uracil-5-) methyltransferase: evidence for covalent catalysis. Biochemistry 26:8599–8606
16.
Zurück zum Zitat Patton JR (1993) Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry 32:8939–8944CrossRefPubMed Patton JR (1993) Ribonucleoprotein particle assembly and modification of U2 small nuclear RNA containing 5-fluorouridine. Biochemistry 32:8939–8944CrossRefPubMed
17.
Zurück zum Zitat Kubota T, Watanabe M, Otani Y, Kitajima M, Fukushiuma M (2002) Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 22:3537–3540PubMed Kubota T, Watanabe M, Otani Y, Kitajima M, Fukushiuma M (2002) Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 22:3537–3540PubMed
Metadaten
Titel
Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients
verfasst von
Seiichirou Hoshino
Yuuichi Yamashita
Takafumi Maekawa
Takayuki Shirakusa
Publikationsdatum
01.12.2005
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 6/2005
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0985-9

Weitere Artikel der Ausgabe 6/2005

Cancer Chemotherapy and Pharmacology 6/2005 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.